contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Bayer’s Finnish operations have a turnover of almost a billion. Bayer pays more corporate tax to Finland.

Denmark has no forests, so there Novo (and a couple of other pharmaceutical companies) are responsible for GDP growth. In Finland, there’s only Orion and some minor players like e.g. Revenio. We’ll have to wait a long time for the pharmaceutical sector here to start dominating GDP volume. Of course, small biotech companies like Faron could also contribute to the growth of national wealth in some distant future

A hint for decision-makers from Kauppalehti: In Denmark, the success of pharmaceutical giant Novo Nordisk is visible at the level of the entire national economy. A significant portion of the country’s GDP growth in recent years has been driven by the pharmaceutical industry. A similar healthcare miracle, visible at the level of the entire economy, would also be possible in Finland, says Jaakko Linna, CEO of Novo Nordisk Finland. “In my opinion, it would require us to be able to make a joint decision here as well, placing the healthcare sector in a position where we expect growth from it. We are ready to invest in this and do it together.”

Press release translated by a translator: Composition of Faron Pharmaceuticals’ Shareholders’ Nomination Board Faron Pharmaceuticals Ltd | Company Announcement | 17 December 2025 at 16:30:00 EET TURKU, FINLAND – Faron Pharmaceuticals Oy. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on treating cancers with novel immunotherapies, today announces that a meeting of the Company’s five largest shareholders has re-elected the following members to Faron Pharmaceuticals Oy’s Shareholders’ Nomination Board:   Timo Syrjälä, representing himself (Chairman)   Erkka Kohonen, representing Keskinäinen työeläkevakuutusyhtiö Varma, and   Joonas Haakana, representing UMO Capital   Faron’s Shareholders’ Nomination Board consists of three members representing the Company’s shareholders. Faron’s Chairman of the Board, Tuomo Pätsi, serves as an expert on the Nomination Board without being a member of the Board. The Shareholders’ Nomination Board prepares and presents to the Annual General Meeting proposals concerning the number, composition, and remuneration of the Board members and the Chairman of the Board. For more information, please contact:     IR Partner    At least for now, Timo continues on the Shareholders’ Nomination Board. It would have been nice to hear about this meeting myself, though it probably wasn’t very long.

Bargain hunters in action? Lottery potential? A lot of people putting in a few euros? Large investors already have a full position? Most importantly: does it matter? A high-risk target in a small market, with a few relatively large long-term owners due to whom a hostile takeover is not really worthwhile. And generally speaking, if I recall correctly, in the autumn of 2022, large investors did not really acquire Wärtsilä, for example, at a price of just over six euros, nor during the following year when the price fluctuated above and below ten euros. I am not convinced of the profitability of following (others’ investments), whether it concerns small or large investors. It might work for traders, though I don’t understand much about the intricacies of that activity. Among my own investments, those thought through by myself have been the most successful, and those followed (from others) the worst. Think for yourself, or something like that.

To me, the progress now looks consistent. The ASH data, as a whole, was promising and supports moving forward. This has always been a very high-risk investment. And for me, the current scarce information is a good sign. It is true that without a partner, this remains a high-risk investment. I personally believe that Phase 3 will be entered with a partner, but the content of the agreement might be a disappointment for many. If you have believed in this before, I would say to keep your cool. To me, things are progressing according to the communicated plan, but naturally, no one can guarantee anything. Wishing everyone a good and peaceful wait for Christmas.

Top 30 ownership:  31.12.2024 - 63,827,292 pcs - 64.20%  16.12.2025 - 64,047,584 pcs - 54.64% So, they haven’t decreased overall, but there are significantly more small investors. Of course, it would be nice to see more institutions as well, but this type of risk immediately rules out quite a few.

Faron Pharmaceuticals

Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk ...

<p>Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk investment as drug development requires frontloaded investments in research, while the success of commercialization is very uncertain. If the drug candidates enter the market, the invested capital can be multiplied. However, failure of drug development is frequent and, in that case, the invested capital may be partially or totally lost. We believe the share provides sufficient expected return to counterbalance the high risk. The share is suitable for a long-term investor that tolerates high risk as part of a well-diversified portfolio. A person investing in Faron must also be prepared for share issues.</p> 

	2021	22e	23e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-21.1	-22.0	-0.8
EBIT-% (adj.)	-527,700.0 %	-550,000.0 %	-19,500.0 %
EPS (adj.)	-0.40	-0.40	-0.02
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Risky investment with huge potential

Key Estimate Figures2022-08-08

Forum discussions